The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
NCT ID: NCT05804331
Last Updated: 2025-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2023-03-14
2028-09-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic Resection Study
NCT02000141
Upper GI Outcomes Following EMR
NCT02305290
Outcomes of Endoscopic Resection of Mucosal and Submucosal Lesions in the Stomach
NCT02306707
The Australian Colonic Large Sessile Lesion Endoscopic Resection Study
NCT03471793
Endoscopic Resection Multicenter Registry
NCT03065257
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Lesion characteristics including histology
* Procedural outcomes
* Safety Outcomes
* Efficacy outcomes
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient with Gastrointestinal neoplasm
Pt referred for resection of gastrointestinal neoplasm. Observational data collected from endoscopic submucosal dissection (ESD), submucosal-tunnelling endoscopic resection (STER) or endoscopic full-thickness resection (EFTR) of gastrointestinal neoplasm
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Lesions for ESD limited to the mucosal and/or submucosal layer OR
* Lesions for EFTR limited to the muscularis propria layer OR
* Lesions for STER limited to the submucosal and/or muscularis propria layer
* Aged 18 years or older
Exclusion Criteria
* Unable to give informed consent
* Pregnant or lactating patients
* Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Western Sydney Local Health District
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Professor Michael Bourke
Director of Endoscopy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Bourke
Role: PRINCIPAL_INVESTIGATOR
WSLHD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Westmead Hospital
Sydney, New South Wales, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022/PID02709
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.